Voyageur Pharmaceuticals Ltd., a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, announced it is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility. The company is conducting a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites, with key criteria including proximity to iodine brine sources, logistics, infrastructure, access to skilled labor, and government incentive packages.
According to the company, strong candidate locations have been identified in the states of Oklahoma and Texas. These jurisdictions offer compelling attributes such as proximity to Voyageur's iodine extraction initiatives in Oklahoma's Anadarko Basin, robust transportation infrastructure including rail, major highways, and port access, as well as access to skilled labor and abundant municipal water supply. The company is actively engaging with economic development authorities across multiple U.S. jurisdictions and will select the final site based on the most attractive overall combination of factors, with a strong emphasis on incentive and support packages.
The pharmaceutical manufacturing facility will receive concentrated iodine liquor produced through Voyageur's proprietary closed-loop Streamlined Iodine Process directly from its Oklahoma brine operations, together with high-purity barite from the Frances Creek project. Unlike conventional contrast media manufacturers that depend on imported iodine flakes or intermediates and energy-intensive synthetic precipitated barium sulfate, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing. Management believes this will deliver the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with superior sustainability and supply security for U.S. hospitals, government customers, and international distribution.
Key anticipated project highlights include cost leadership through vertical integration, significant opportunities for U.S. federal and state support, and the creation of 150–250 direct high-skilled positions in manufacturing, engineering, quality assurance, laboratory, and operations, plus substantial indirect jobs through construction and suppliers. Once at full scale, the facility is expected to generate significant annual economic activity, major local tax revenue, and support for regional supply chains. The company also plans collaboration with post-secondary institutions to establish pharmaceutical training programs, co-op placements, and talent pipelines in chemical engineering and pharmaceutical sciences.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. We are evaluating multiple strong jurisdictions and will select the site that delivers the most compelling overall package, including the strongest incentive support. The jurisdiction that provides Voyageur with the most significant incentive package will secure this transformative project and its substantial long-term economic benefits.”
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other customary conditions. This announcement builds on Voyageur's ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. The company continues to work closely with economic development corporations and state/federal partners to advance incentives and permitting. Management believes the project aligns with U.S. priorities for domestic critical and strategic minerals, pharmaceutical onshoring of strategic drugs, and rural economic development.
